These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

696 related items for PubMed ID: 8629037

  • 1. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U, Harstrick A, Wilke H, Seeber S.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 3. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U, Wilke H, Pari CP, Strumberg D, Harstrick A, Eberhardt W, Becher R, Diergarten K, Seeber S.
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
    Paul DM, Garrett AM, Meshad M, DeVore RD, Porter LL, Johnson DH.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
    [Abstract] [Full Text] [Related]

  • 5. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
    Klaassen U, Wilke H, Müller C, Borquez D, Harstrick A, Seeber S.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
    [Abstract] [Full Text] [Related]

  • 6. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U, Wilke H, Seeber S.
    J Infus Chemother; 1996 Oct; 6(3):127-32. PubMed ID: 9229323
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
    Tolcher AW, Gelmon KA.
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):28-32. PubMed ID: 7638639
    [Abstract] [Full Text] [Related]

  • 12. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ, Thomssen C, duBois A, Lisboa BW, Untch M, Kuhnle H, Konecny G, Janicke F, Meerpohl HG, Lindner C, Hecker D, Diergarten K.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [Abstract] [Full Text] [Related]

  • 17. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K, Happich K, Schirner I, Jüngert B, Brückl V, Männlein G, Brückl WM, Merkel S, Göhl J, Hohenberger W, Hahn EG, Wein A.
    Anticancer Res; 2004 Feb; 24(1):385-91. PubMed ID: 15015625
    [Abstract] [Full Text] [Related]

  • 18. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM, Colarusso P, Goldberg M, Dresler C, Coia LR.
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [Abstract] [Full Text] [Related]

  • 19. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [Abstract] [Full Text] [Related]

  • 20. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.